Advertisement
open access
Medical Conferences
Conference Reports
2024 Medicom Conference Planning
Conference Proceedings
Disease Areas
Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
Conference Proceedings
2024 Medicom Conference Planning
Home
>
Oncology
>
ASCO 2019
ASCO 2019
American Society of Clinical Oncology
31 May – 4 June 2019, Chicago, USA
Read the full Report (e-book)
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editors
Editor
Dr Erlinda Maria Gordon, Dr Sant P. Chawla
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Presented By
Dr Sara A. Hurvitz, University of California, Los Angeles, Jonsson Comprehensive Cancer Centre
Breast Cancer
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Presented By
Dr Sara A. Hurvitz, University of California, Los Angeles, Jonsson Comprehensive Cancer Centre
Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer
Presented By
Dr Ian E. Krop, Dana-Farber Cancer Institute, USA
ImPassion130 brings breast cancer into the immunotherapy era
Melanoma
Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma
Presented By
Prof. Mario Mandalà, Papa Giovanni XXIII Cancer Centre Hospital, Bergamo, Italy
Long term quality of life with nivolumab, or in combination (ipilimumab) in advanced melanoma
Kidney Cancer
Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours
Presented By
Prof. Bernhard Escudier, Gustave Roussy Cancer Campus, Paris, France
Sarcoma
Olaratumab trial in soft tissue sarcoma fails to meet overall survival endpoint
Presented By
Dr William D. Tap, Memorial Sloan Kettering Cancer Centre, USA
Gastrointestinal Cancers
FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis
Presented By
Dr Javier Sastre, Hospital Clínico San Carlos, Spain
KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer
Presented By
Dr Josep Tabernero, Vall d’Hebron University Hospital, Spain
Neoadjuvant chemotherapy as a potential treatment option in colon cancer
Presented By
Dr Matthew T. Seymour, National Institute for Health Research Clinical Research Network, England
Laparascopic surgery; less morbidity, same survival benefits as open surgery in colorectal cancer with liver metastases
Presented By
Dr Åsmund Avdem Fretland, Oslo University Hospital, Norway
Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer
Presented By
Dr Hedy L. Kindler, The University of Chicago, USA
Hematologic Malignancies
Daratumumab a promising treatment option for transplant-eligible multiple myeloma
Presented By
Dr Philippe Moreau, University Hospital Hôtel-Dieu, France
Rituximab/lenalidomide regimen shows clinical benefit in non-hodgkin lymphoma trials
Paediatric Oncology
Entrectinib produces rapid and durable responses in children with refractory CNS and solid tumours
Presented By
Dr Giles W. Robinson, St. Jude Children’s Research Hospital, USA
Head and Neck Cancer
Ado-trastuzumab emtansine a potential new treatment option for HER2-amplified advanced salivary gland cancer
Presented By
Dr Bob T. Li, Memorial Sloan Kettering Cancer Centre, USA
Sentinel lymph node biopsy shows promise for early oral cancer
Presented By
Dr Yasuhisa Hasegawa, Asahi University Hospital, Japan
Genitourinary Cancer - Prostate Cancer
Enzalutamide offers survival advantage over other NSAAs in mHSPC
Presented By
Dr Christopher Sweeney, Dana-Farber Cancer Institute, USA
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer
Presented By
Dr Kim N. Chi, BC Cancer Agency, Canada
Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma
Presented By
Dr Daniel P. Petrylak, Yale School of Medicine, USA
Multiple Myeloma
Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma
Presented By
Dr Paul G. Richardson, Dana-Farber Cancer Institute/Harvard Medical School, USA
Lung Cancer
Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC
Presented By
Dr Tina Cascone, University of Texas MD Anderson Cancer Centre, USA
Overcoming the challenges of immunotherapy in non–small cell lung cancer
Presented By
Dr Sarah B. Goldberg, Dr Melissa Lynne Johnson, Dr Alexander Chi
Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC
Presented By
Dr Byoung Chul Cho, Yonsei Cancer Centre, South Korea
Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC
Presented By
Dr Edward B. Garon, David Geffen School of Medicine, USA
Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC
Presented By
Dr Justin F. Gainor, Massachusetts General Hospital, USA
Lurbinectedin shows promise as second-line therapy for SCLC
Presented By
Dr Luis G. Paz-Ares, Hospital Universitario 12 de Octubre, Spain
Early results from TAK-788 in NSCLC with EGFR exon 20 insertions
Presented By
Dr Gregory Riely, Memorial Sloan Kettering Cancer Centre, USA
Developmental Therapeutics - Immunotherapy
IL-6 and C-reactive protein as potential biomarkers for checkpoint inhibition
Presented By
Dr Jeffrey S. Weber, Laura and Isaac Perlmutter Cancer Centre, USA
First-in-human study shows IL1RAP-targeting drug safe in solid tumours
Presented By
Dr Ahmad Awada, Institut Jules Bordet, Belgium